NASDAQ:AVTE Aerovate Therapeutics (AVTE) Stock Price, News & Analysis $2.58 +0.15 (+6.17%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Aerovate Therapeutics Stock (NASDAQ:AVTE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aerovate Therapeutics alerts:Sign Up Key Stats Today's Range$2.44▼$2.6050-Day Range$2.43▼$2.7052-Week Range$1.25▼$32.42Volume249,881 shsAverage Volume163,225 shsMarket Capitalization$74.51 millionP/E RatioN/ADividend YieldN/APrice Target$2.25Consensus RatingHold Company OverviewAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Read More… Aerovate Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks21st Percentile Overall ScoreAVTE MarketRank™: Aerovate Therapeutics scored higher than 21% of companies evaluated by MarketBeat, and ranked 872nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingAerovate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageAerovate Therapeutics has received no research coverage in the past 90 days.Read more about Aerovate Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aerovate Therapeutics are expected to grow in the coming year, from ($2.64) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aerovate Therapeutics is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aerovate Therapeutics is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAerovate Therapeutics has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aerovate Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.86% of the float of Aerovate Therapeutics has been sold short.Short Interest Ratio / Days to CoverAerovate Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aerovate Therapeutics has recently increased by 35.48%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAerovate Therapeutics does not currently pay a dividend.Dividend GrowthAerovate Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.86% of the float of Aerovate Therapeutics has been sold short.Short Interest Ratio / Days to CoverAerovate Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aerovate Therapeutics has recently increased by 35.48%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.71 News SentimentAerovate Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Aerovate Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for AVTE on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aerovate Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.90% of the stock of Aerovate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Aerovate Therapeutics' insider trading history. Receive AVTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AVTE Stock News HeadlinesReviewing Bioxytran (OTCMKTS:BIXT) and Aerovate Therapeutics (NASDAQ:AVTE)January 19 at 2:34 AM | americanbankingnews.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Up 35.5% in DecemberJanuary 18 at 3:33 AM | americanbankingnews.comGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now. January 20, 2025 | Crypto 101 Media (Ad)Traders Purchase High Volume of Aerovate Therapeutics Call Options (NASDAQ:AVTE)January 17 at 3:59 AM | americanbankingnews.comUnusually active option classes on open January 16thJanuary 16, 2025 | markets.businessinsider.comCritical Review: Kronos Bio (NASDAQ:KRON) versus Aerovate Therapeutics (NASDAQ:AVTE)January 11, 2025 | americanbankingnews.comAVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to ShareholdersDecember 28, 2024 | businesswire.com$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of BMTX, AVTE, ALTR and PFIENovember 13, 2024 | stockhouse.comSee More Headlines AVTE Stock Analysis - Frequently Asked Questions How have AVTE shares performed this year? Aerovate Therapeutics' stock was trading at $2.65 at the start of the year. Since then, AVTE shares have decreased by 2.6% and is now trading at $2.58. View the best growth stocks for 2025 here. How were Aerovate Therapeutics' earnings last quarter? Aerovate Therapeutics, Inc. (NASDAQ:AVTE) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.56) earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $0.03. When did Aerovate Therapeutics IPO? Aerovate Therapeutics (AVTE) raised $100 million in an initial public offering (IPO) on Wednesday, June 30th 2021. The company issued 7,150,000 shares at $13.00-$15.00 per share. Who are Aerovate Therapeutics' major shareholders? Top institutional investors of Aerovate Therapeutics include FNY Investment Advisers LLC (0.26%). Insiders that own company stock include David S Grayzel, Hunter Gillies, George A Eldridge, Ralph Niven, Benjamin T Dake, Marinus Verwijs and Timothy P Noyes. View institutional ownership trends. How do I buy shares of Aerovate Therapeutics? Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aerovate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aerovate Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Palo Alto Networks (PANW), Tesla (TSLA) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings11/12/2024Today1/20/2025Next Earnings (Estimated)3/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVTE CUSIPN/A CIK1798749 Webaerovatetx.com Phone617-443-2400FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$2.25 High Stock Price Target$3.00 Low Stock Price Target$2.00 Potential Upside/Downside-12.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,520,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-90.19% Return on Assets-77.47% Debt Debt-to-Equity RatioN/A Current Ratio8.78 Quick Ratio8.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.96 per share Price / Book0.65Miscellaneous Outstanding Shares28,880,000Free Float21,685,000Market Cap$74.51 million OptionableOptionable Beta1.00 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:AVTE) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.